Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb (or BMS), joins a16z Bio + Health general partner Jorge Conde.
Together, they talk about how AI could transform drug discovery and development at a large biopharma company—and how a company might have to adapt to harness AI; modalities they’re excited about; and Greg’s do’s and don’ts for startups looking to partner with a company like BMS.
AI and Actionable Insights for Drug Development with Daphne Koller
Journal Club: Remodeling Oncogenic Transcriptomes with Ben Cravatt and Gene Yeo
Health System Partnerships with Tommy Ibrahim
From the Archives: The Art & Science of Biology's Future with Jennifer Doudna
The Power of a Platform Company with Josh Mandel-Brehm
Culture and Company Building with Sam Corcos
Payments & Payors: Fintech's Role with Kurt Adams
American Optimism with Joe Lonsdale
Going to Market in Healthcare: B2C2B
Advancing the Field of Immunotherapeutics
Healthspan, Lifespan, and the Biology of Aging
Payors and Providers Post-Pandemic
Using AI to Take Bio Farther
Expert AI as a Healthcare Superpower
Cultivated Meat: Challenges, Opportunities, Future
AI is Here. Now What?
Regulatory Trends in Telehealth
Demystifying DC: Opportunities for Collaboration
The Consolidated Drug Channel and Cash-Pay Drugs
Bio x Games: Is a Fun, Therapeutic Game Possible?
Create your
podcast in
minutes
It is Free